* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download cells, exhibit the morphology and growth properties of
Cytokinesis wikipedia , lookup
Cell growth wikipedia , lookup
Extracellular matrix wikipedia , lookup
Cell encapsulation wikipedia , lookup
Tissue engineering wikipedia , lookup
Cell culture wikipedia , lookup
Organ-on-a-chip wikipedia , lookup
List of types of proteins wikipedia , lookup
Cellular differentiation wikipedia , lookup
Hematopathology Monika Klimkowska MD PhD Klinisk patologi/cytologi [email protected] 1. Normal hematopoiesis - WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2. Introduction to hematopathological diagnostics Hematopoesis • From Greek: hem (αἷμα) = blood, poes (ποιεῖν) = make, create • Generation of all types of blood cells • All blood cells – derived from embryonic connective tissue (mesenchyme) • Hematopoiesis appears around 14th day of gestation Embryonal hematopoiesis • First blood islands – present in yolk sac 3-4 wks after conception – contain hemangioblasts (precursors to blood cells & endothelial cells) • First hematopoietic line in embryo: red cell series – primitive megaloblastic erythropoiesis – definitive normoblastic e-poiesis • Progenitors & pluripotent stem cells migrate via vessels to liver (from 5th-6th wk), then to bone marrow (from 4th-5th mo) • Fetal hematopoiesis – higher turnover, shorter cell lifespan, no or few growth factors required Erythropoietic cells, 55 days of gestation Hematopoiesis during lifetime Distribution of red BM during lifetime Stem cell concept • Stem cells – reside in specific locations (niches) – are not fully differentiated (as opposed to mature cells in same tissue) – have controlled but robust proliferative potential for the lifetime of host tissue – each SC can regenerate both stem & differentiated cells – have capacity to divide into two daughter cells • one that retains all properties of parental cell (self-renewal) • the other that undergoes differentiation specific for the tissue Stem cell hierarchy • Totipotent SC – gives rise to both embryo & placenta (fertilized oocyte, zygote or first blastomere) • Pluripotent SC – gives rise to all three germ layers of the embryo (ICM of blastocyts, embryonic SC, embryonic germ cells EG, epiblast derived stem cells ESC) • Multipotent SC – gives rise to one germ cell layer only (ecto-, endo- or mesoderm) • Monopotent SC – tissue-committed SC, gives rise to cells of one lineage, eg hematopoietic SC (HSC), intestinal epithelium SC, neural SC, liver SC, skeletal muscle SC Stem cell hierarchy Nobel Prize 2012 • • • • AN important problem in embryology is whether the differentiation of cells depends upon a stable restriction of the genetic information contained in their nuclei. The technique of nuclear transplantation has shown to what extent the nuclei of differentiating cells can promote the formation of different cell types (e.g. King & Briggs, 1956; Gurdon, 1960c). Yet no experiments have so far been published on the transplantation of nuclei from fully differentiated normal cells. This is partly because it is difficult to obtain meaningful results from such experiments. The small amount of cytoplasm in differentiated cells renders their nuclei susceptible to damage through exposure to the saline medium, and this makes it difficult to assess the significance of the abnormalities resulting from their transplantation. It is, however, very desirable to know the developmental capacity of such nuclei, since any nuclear changes which are necessarily involved in cellular differentiation must have already taken place in cells of this kind. The experiments described below are some attempts to transplant nuclei from fully differentiated cells. Many of these nuclei gave abnormal results after transplantation, and several different kinds of experiments have been carried out to determine the cause and significance of these abnormalities. The donor cells used for these experiments were intestinal epithelium cells of feeding tadpoles. This is the final stage of differentiation of many of the endoderm cells whose nuclei have already been studied by means of nuclear transplantation experiments in Xenopus. The results to be described here may therefore be regarded as an extension of those previously obtained from differentiating endoderm cells (Gurdon, 1960c). GURDON JB. J Embryol Exp Morphol. 1962 Dec;10:622-40. Nobel Prize 2012 • • • • Differentiated cells can be reprogrammed to an embryonic-like state by transfer of nuclear contents into oocytes or by fusion with embryonic stem (ES) cells. Little is known about factors that induce this reprogramming. Here, we demonstrate induction of pluripotent stem cells from mouse embryonic or adult fibroblasts by introducing four factors, Oct3/4, Sox2, c-Myc, and Klf4, under ES cell culture conditions. Unexpectedly, Nanog was dispensable. These cells, which we designated iPS (induced pluripotent stem) cells, exhibit the morphology and growth properties of ES cells and express ES cell marker genes. Subcutaneous transplantation of iPS cells into nude mice resulted in tumors containing a variety of tissues from all three germ layers. Following injection into blastocysts, iPS cells contributed to mouse embryonic development. These data demonstrate that pluripotent stem cells can be directly generated from fibroblast cultures by the addition of only a few defined factors. Takahashi and Yamanaka, Cell 126(4):663-676, 2006 revoseek.com Stem cell niches Bone marrow HSC CMP – common myeloid progenitor CLP – common lymphoid progenitor HSC niche in bone marrow BM blood supply Blood cell release from BM Mobilization of HSCs Stem cell Bone marrow aspirate Bone marrow aspirate - smear megakaryocytes Hematopoiesis overview LT-HSC = long term hematopoietic stem cell ST-HSC = short term HSC TFs involved in hematopoiesis Hematopoiesis - cytokines 2008 4th Edition 2016 Update (not published yet, 3 papers in Blood) New edition planned 2018? WHO 2008 Myeloid diseases Lymphoid diseases • • • • • • • Myeloproliferative neoplasms Myeloid/lymphoid neoplasms with eosinophilia & abnormalities of PDGFRA, PDGFRB or FGFR1 Myelodysplastic/myeloproliferative neoplasms Myelodysplastic syndromes Acute myeloid leukemia and related precursor neoplasms Acute leukemias of ambiguous lineage • • • Precursor lymphoid neoplasms (B-, Tcells) Mature B-cell neoplasms (B-NHL), including plasma cell diseases Mature T- cell (T-NHL) and NK-cell neoplasms Hodgkin lymphoma •Histiocytic and dendritic cell neoplasms •Post-transplant lymphoproliferative disordes Erythropoiesis Erythroid island Chasis Blood 2008 Erythron Proerythroblast Basophilic erythroblast Polychromatophilic erythroblast Orthochromatic Reticulocyte erythroblast Erythropoiesis Granulocytopoiesis Granulocytopoiesis - cytokines Granulocytopoiesis - localisation Monocytopoiesis/dendritic cells Granulocytes • Have phagocytic properties • Act ”on demand”, answering to tissue injury/inflammation/infection • Move to inflammation site within several hours) • Relatively short-lived (up to 6 days, die at the site) Granulocytes • Neutrophils: – azurophilic granules – myeloperoxidase, defensins, proteases (elastase, cathepsin), BPI – specific (seondary) granules – lysozyme, collagenase, alkaline phosphatase, NADPH oxidase, lactoferrin – tertiary granules – gelatinase, cathepsin • Eosinophils: MBP, peroxidase, lipase, Rnase, plasminogen, histamine • Basophils: histamine, elastase, phospholipase, proteoglycans (heparin, chondroitin) • Mast cells: also granulated but not granulocytes(!), contain histamine, heparin Monocytes/macrophages • Move actively • Undergo terminal differentiation at the site • Major phagocytes (direct phagocytosis or followed by opsonisation) • Major antigen presenters • Dendritic cells – multiple subpopulations for different purposes/at different locations (skin, lymph nodes, respiratory tract, GI tract) • Lymphoid vs myeloid vs plasmacytoid DCs Megakaryocytopoiesis Megakaryoblast Promegakaryocyte Megakaryocyte (with emperipolesis) How a MGK produces platelets? Thrombocytes • Granules: – dense (delta) – Ca, serotonin, ADP, ATP – lambda – hydrolytic enzymes – alpha – P-selectin, PF4, vWF, fibrinogen, PDGF, TGF-beta, coagulation factors V and XIII Produce TXA2 (arachidonic acid pathway) Glycoprotein receptors B-cell development B-cell distribution Primary vs secondary lymphatic organs MATURE B-CELL NEOPLASMS • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • Chronic lymphocytic leukemia /small lymphocytic lymphoma Monoclonal B-cell lymphocytosis* B-cell prolymphocytic leukemia Splenic marginal zone lymphoma Hairy cell leukemia Splenic B-cell lymphoma/leukemia, unclassifiable Splenic diffuse red pulp small B-cell lymphoma Hairy cell leukemia-variant Lymphoplasmacytic lymphoma Waldenstrom macroglobulinemia Monoclonal gammopathy of undetermined significance (MGUS), IgM* Mu heavy chain disease Gamma heavy chain disease Alpha heavy chain disease Monoclonal gammopathy of undetermined significance (MGUS), IgG/A* Plasma cell myeloma Solitary plasmacytoma of bone Extraosseous plasmacytoma Monoclonal immunoglobulin deposition diseases* Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) Nodal marginal zone lymphoma Pediatric nodal marginal zone lymphoma Follicular lymphoma In situ follicular neoplasia* Duodenal-type follicular lymphoma* Pediatric-type follicular lymphoma* Large B-cell lymphoma with IRF4 rearrangement* Primary cutaneous follicle center lymphoma Mantle cell lymphoma In situ mantle cell neoplasia* • • • • • • • • • • • • • • • • • • • • • • Diffuse large B-cell lymphoma (DLBCL), NOS Germinal center B-cell type* Activated B-cell type* T cell/histiocyte-rich large B-cell lymphoma Primary DLBCL of the CNS Primary cutaneous DLBCL, leg type EBV positive DLBCL, NOS* EBV+ Mucocutaneous ulcer* DLBCL associated with chronic inflammation Lymphomatoid granulomatosis Primary mediastinal (thymic) large B-cell lymphoma Intravascular large B-cell lymphoma ALK positive large B-cell lymphoma Plasmablastic lymphoma Primary effusion lymphoma HHV8 positive DLBCL, NOS* Burkitt lymphoma Burkitt-like lymphoma with 11q aberration* High grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements* High grade B-cell lymphoma, NOS* B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma T-cell development in thymus T-cell subsets NK-cells MATURE T-AND NK-NEOPLASMS • • • • • • • • • • • • • • • • • • • • • • • • • • • • • T-cell prolymphocytic leukemia T-cell large granular lymphocytic leukemia Chronic lymphoproliferative disorder of NK cells Aggressive NK cell leukemia Systemic EBV+ T-cell Lymphoma of childhood* Hydroa vacciniforme-like lymphoproliferative disorder* Adult T-cell leukemia/lymphoma Extranodal NK/T-cell lymphoma, nasal type Enteropathy-associated T-cell lymphoma Monomorphic epitheliotropic intestinal T-cell lymphoma* Indolent T-cell lymphoproliferative disorder of the GI tract * Hepatosplenic T-cell lymphoma Subcutaneous panniculitis- like T-cell lymphoma Mycosis fungoides Sezary syndrome Primary cutaneous CD30 positive T-cell lymphoproliferative disorders Lymphomatoid papulosis Primary cutaneous anaplastic large cell lymphoma Primary cutaneous gamma-delta T-cell lymphoma Primary cutaneous CD8 positive aggressive epidermotropic cytotoxic T-cell lymphoma Primary cutaneous acral CD8+ T-cell lymphoma* Primary cutaneous CD4 positive small/medium T-cell lymphoproliferative disorder* Peripheral T-cell lymphoma, NOS Angioimmunoblastic T-cell lymphoma Follicular T-cell lymphoma* Nodal peripheral T-cell lymphoma with TFH phenotype* Anaplastic large cell lymphoma, ALK positive Anaplastic large cell lymphoma, ALK negative * Breast implant-associated anaplastic large cell lymphoma* HODGKIN LYMPHOMA HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS • • • • • • • • • • • • • • • Nodular lymphocyte predominant Hodgkin lymphoma Classical Hodgkin lymphoma Nodular sclerosis classical Hodgkin lymphoma Lymphocyte-rich classical Hodgkin lymphoma Mixed cellularity classical Hodgkin lymphoma Lymphocyte-depleted classical Hodgkin lymphoma POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD) • • • • • • Plasmacytic hyperplasia PTLD Infectious mononucleosis PTLD Florid follicular hyperplasia PTLD* Polymorphic PTLD Monomorphic PTLD (B- and T/NK-cell types) Classical Hodgkin lymphoma PTLD Histiocytic sarcoma Langerhans cell histiocytosis Langerhans cell sarcoma Indeterminate dendritic cell tumour Interdigitating dendritic cell sarcoma Follicular dendritic cell sarcoma Fibroblastic reticular cell tumour Disseminated juvenile xanthogranuloma Erdheim/Chester disease* Hematopathology - diagnostics Types of samples Possible analyses Bone marrow aspirate morphology (histology + cytology), immunophenotyping, molecular analyses (FISH, PCR), cytogenetics Bone marrow biopsy morphology (histology + cytology), immunophenotyping, molecular analyses (FISH) Peripheral blood morphology (cytology), immunophenotyping, molecular analyses Cerebrospinal fluid morphology (cytology), immunophenotyping Fine needle aspirate (LN, focal lesions) morphology (cytology), immunophenotyping, molecular analyses Tissue biopsies morphology (histology + cytology), immunophenotyping, molecular analyses (FISH, PCR) What cannot be done? Cytogenetics, PCR Molecular analyses? Tissue biopsies = core biopsies, small biopsies or resectates - LN, parenchymatous organs, endoscopic material Other body fluids (ascitic fluid, fluid from pleural cavity/pericardial sac etc) – same as FNAB Cytogenetics, flow cytometry – only on fresh material BM provtagning – när och varför? • Utredning av cytopenier/abnormt förhöjda blodvärden • Efter lymfomdiagnos – staging (bedömnign av sjukdomens utbredning) • M-komponent i blod/urin • Kontroll efter behandling av hematologiska maligniteter • Kontroll efter SCT för t ex aplastisk anemi BM provtagning – biopsi eller aspirat? • Aspirat + tunnare nål (mindre smärta?) + snabbare bearbetning - endast cellsuspension (=cytologisk analys) - svårare att ta ut celler vid t ex fibros (dry tap) • Biopsi + ger vävnadsmaterial (=histologisk analys, med information om bentrabeklar, stroma, topografi, typ av patologisk infiltration) + enda möjlighet om inget aspirat fås + materialet kan arkiveras - grövre nål - tar längre tid att bearbetas, kräver urkalkning Rutiner kring materialhantering • Om ”hematologisk” (Lymfom? Cancer?) frågeställning på remissen – fallet hanteras av hematopatologigruppen = färskhantering & utskärning, med biobanking • → FACS svar samma/nästa dag • → svar på små biopsier inom max två dagar Routine analysis - morphology Peripheral blood - smear Bone marrow – AML Bone marrow – aplastic anemia Peripheral blood - abnormalities anemi leukocytos PB – abnormalities (2) Akut lymfoblastisk leukemi Akut myeloisk leukemi PB – abnormalities (3) Kronisk lymfocytisk leukemi Kronisk myeloisk leukemi PB – abnormalities (4) Hemolysis Iron-deficiency anemia Special techniques Molecular analyses • Detect certain DNA/RNA fragments • Detect RNA translation products – abnormal proteins resulting from e.g. translocations between two genes on different chromosomes • Qualitative analysis (yes/no) → diagnosis • Quantitative analysis (how many copies/aberrant cells) → follow-up after treatment • MRD = minimal residual disease Phenotyping • Flow cytometry (suspension of living cells) – – – – markers on cell membranes markers in the cytoplasm markers in the nucleus phenotype, cell size & granulation • Immunohistochemistry (fresh frozen or FFPE material) – markers on the surface/inside cells – topographical information (phenotype+location) – material can be stored for many years • FFPE = formalin-fixed paraffin.embedded Immunologic background Major histocompatibility complex (MHC) • Family of molecules on cell surface • Present in all vertebrates • Aim: to help cells recognize own/foreign cells (self/non-self) • In humans: human leukocyte antigen (HLA) system. • Classes of MHC protein molecules – class I MHC – on almost every cell in the organism – class II – only on leukocytes – class III – complement cascade, interleukins • Flow cytometry/IHC detect MHC antigens using monoclonal antibodies Flow cytometry BMWS0289 FACS of lytic bone lesion Much fewer cells available for analysis with intracellular markers but clonality pattern consistent with mIg BMWS0289 MC2317-13 CD138 CD20 CD79a BMWS0289 T12608-13 CD138 CD79a CD20 IgM